Enveric Biosciences (ENVB)
(Delayed Data from NSDQ)
$0.75 USD
-0.01 (-1.42%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $0.76 +0.01 (1.33%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ENVB 0.75 -0.01(-1.42%)
Will ENVB be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ENVB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENVB
Enveric Biosciences, Inc. (ENVB) Stock Falls Amid Market Uptick: What Investors Need to Know
Enveric Biosciences, Inc. (ENVB) Stock Declines While Market Improves: Some Information for Investors
ENVB: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for April 17th
What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock
New Strong Buy Stocks for April 12th
Other News for ENVB
Psychedelic stocks fall as FDA panel rejects MDMA therapy
FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD (updated)
FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD
Psychedelic stocks mixed as FDA comments on MDMA therapy
Psychedelic stocks mixed as FDA comments on MDMA therapy (update)